TCP-25 is a synthetic peptide derived from the body’s innate immune system, the primary defense against injury and infection. It exerts a multi-modal mode of action that reduce excessive inflammation, reduce exudation, and neutralize pathogenic bacteria; factors that critically impair wound healing in Epidermolysis Bullosa (EB) and other severe dermatological disorders. By addressing these fundamental pathological processes, TCP-25 has the potential to restore effective tissue repair, accelerate wound closure, and ultimately improve patient outcomes.

Resulting in key effects:

• Reduces excessive harmful inflammation
• Controls infection – also effective against AMR and fungi
• Reduces exudation

Leading to multiple therapeutic effects:

• Improves wound healing
• Reduces pain
• Prevents and treats infections
• Improves wound environment through reduced exudation

Ultimate treatment goals:

• Reduce total wound burden
• Reduce scarring
• Reduce risk of skin cancer
• Reduce the frequency of painful dressing changes

Therapeutic area
TCP-25 is developed for conditions characterized by dysfunctional healing, and our primary focus is to improve life of patients suffering from Epidermolysis Bullosa (EB). EB is a group of rare genetic, severe and life-threatening diseases with chronic inflammation and very fragile skin. The disease is manifested as skin blistering, erosion, and ulceration associated with severe painful wounds that are hard to heal, high risk of infection and often disabling scarring.

Current stage
After an extensive preclinical development and a successfully completed Phase I study in three parts, also including patients with EB, we are now preparing for a Phase 2/3 clinical trial in EB.

Learn more about TCP-25 and its application